Market Overview

The UK biotechnology market was valued at USD 22.00 Billion in 2024 and is projected to reach USD 41.47 Billion by 2033, growing at a CAGR of 7.22% during the forecast period of 2025-2033. The market growth is driven by rising chronic disease incidences, government support, increased investments in biotech startups, and advancements in genomics and gene-editing technologies like CRISPR. Furthermore, biotechnology's role in sustainable agriculture and personalized medicine strengthens the market position.

UK Biotechnology Market.

 Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

UK Biotechnology Market Key Takeaways

• The UK biotechnology market was valued at USD 22.00 Billion in 2024.
• The market is expected to grow at a CAGR of 7.22% between 2025 and 2033.
• The forecast period spans from 2025 to 2033, projecting a market value of USD 41.47 Billion by 2033.
• The industry is propelled by increasing chronic diseases, technological advancements in genomics, and government-backed initiatives such as UKRI and Innovate UK.
• NHS Genomic Medicine Service processed over 810,000 genomic tests in 2024, marking an 8% growth from the previous year.
• British public opinion favors gene editing, with 69% supporting it as a means for sustainable agriculture.

Sample Request Link: https://www.imarcgroup.com/uk-biotechnology-market/requestsample

Market Growth Factors

The UK biotechnology industry is fueled by "the increasing prevalence of chronic and genetic diseases, leading to an intensified search for innovative therapies." Improvements in Polymerase Chain Reaction (PCR) technology, miniaturized portable instruments, robotics, and increased research expenditures also fueled biotechnology industry expansion in the UK. The introduction of genomic medicine services, in which care is delivered according to genomic information, emphasizes the importance of biotechnology in precision medicine.

The large public funding in the country, by bodies such as UK Research and Innovation (UKRI) and Innovate UK, acts as a backbone in financing early-stage startups and research institutions. Innovate UK’s budget, which is £1.1 billion every year, helps 450,000 innovators annually, with each pound generating £3.61 in the private sector. Other initiatives, such as Life Sciences Vision 2030 or R&D tax credits, also encourage private investments.

The growing need for sustainable crop solutions fuels the demand in the market. Biotechnology benefits through genetically modified (GM) crops, which are resistant to pests, diseases, and weather. Social acceptance of gene editing to produce resilient food has been reflected by the support of 69% of British adults. Furthermore, bio-fertilizers and bio-pesticides from the advancements in biotechnology aim to promote safety in the environment and improvement of the soil.

Market Segmentation

By Product Type:

• Instruments
• Reagents: Comprising 45.8% market share, reagents are essential for biochemical reactions, cell culture, and molecular biology across applications such as drug discovery, genomics, and diagnostics. The segment benefits from advancements like enzyme-linked reagents and PCR kits, enhancing research sensitivity.
• Software and Services

By Technology:

• Nanobiotechnology
• Tissue Engineering and Regeneration
• DNA Sequencing: The largest technology segment holding 36.8%, driven by next-generation sequencing (NGS), crucial for genomics, personalized medicine, and molecular diagnostics. Supports projects like the 100,000 Genomes Project.
• Cell-Based Assays
• Fermentation
• PCR Technology
• Chromatography
• Others

By Application:

• Healthcare: Dominating with a 49.6% share, healthcare applications include drug discovery, gene therapy, personalized medicine, and molecular diagnostics addressing cancer, cardiovascular diseases, and rare genetic disorders.
• Food and Agriculture
• Natural Resources and Environment
• Industrial Processing
• Bioinformatics
• Others

Regional Insights

London leads the UK biotechnology market due to its world-class research universities, advanced healthcare infrastructure, and vibrant biotech startup ecosystem. The South East benefits from proximity to London and hosts several science parks and R&D centers fostering pharmaceutical and biotech innovation. The North West emphasizes bioprocessing and healthcare biotech with NHS partnerships, while the East of England excels in genomics and agricultural biotechnology. Other regions like Scotland, West Midlands, Yorkshire and The Humber, and East Midlands also contribute notably through unique life sciences initiatives and industrial collaborations.

Recent Developments & News

• March 2025: Celex Oncology unveiled an investigational cancer treatment targeting sodium overload, using VGSC inhibitors and monoclonal antibodies.
• February 2025: Biocon Ltd launched Liraglutide in the UK for diabetes and obesity management, becoming the first generics company with MHRA approval.
• February 2025: Sortera Bio commercialized an AI-powered Deep Screening platform developed at MRC Laboratory of Molecular Biology, accelerating therapeutic discovery.
• February 2025: Tropic advanced non-browning banana development using CRISPR and expanded TR4-resistant banana trials, securing global regulatory approvals and USD 80 Million funding.
• January 2025: Verdiva Bio launched as a clinical-stage biopharmaceutical company focusing on obesity and cardiometabolic therapies, securing USD 411 Million Series A financing.

Competitive Landscape

The competitive environment is highly dynamic and innovation-centric, featuring established firms, startups, research organizations, and academic partnerships. Companies focus on next-generation therapeutics, diagnostics, and agri-biotechnology products, leveraging technologies like CRISPR, AI-based drug discovery, and bioinformatics. Strategic alliances and acquisitions are common to expand technological and geographic reach. Government-funded innovation centers support collaboration and quick translation of research to market.

Key Players

• Celex Oncology
• Biocon Ltd
• Sortera Bio
• Tropic
• Verdiva Bio

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization:https://www.imarcgroup.com/request?type=report&id=24913&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302